Interventional vascular device-focused Centerline Biomedical said Wednesday it closed a $1.7 million seed investment round of financing to support its vascular surgical navigation system.
The system, based on research from the Cleveland Clinic’s Heart & Vascular Institute, is designed to aid surgeons navigating endovascular aneurism repair procedures, with plans to expand to a variety of different vascular procedures, the Cleveland, Ohio-based company said.
“Centerline is very pleased with this investment. The combination of unsafe radiation levels, lengthy procedure times, and limited imaging capacity created an urgent opportunity to solve a real problem for hospitals and patients everywhere,” CEO William Fuller said in a press release.
The device will reduce the amount of radiation exposure needed during surgery, normally used to guide devices into positions, Centerline said. The Centerline system is completely radiation-free, the company added.
“The opportunity to positively impact a growing number of patients and providers alike is significant. Centerline’s platform technology solves an immediate need and has the ability to transform many vascular and non-vascular procedures by reducing radiation, improving outcomes and saving costs,” medical advisory board chair Dr. Matthew Eagleton said in prepared remarks.